Alterity Therapeutics Ltd
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-… Read more
Alterity Therapeutics Ltd (ATHE) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.192x
Based on the latest financial reports, Alterity Therapeutics Ltd (ATHE) has a cash flow conversion efficiency ratio of -0.192x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.43 Million) by net assets ($54.21 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Alterity Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how Alterity Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Alterity Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alterity Therapeutics Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Anhui Xinbo Aluminum Co Ltd
SHE:003038
|
-0.140x |
|
Kernel Holding SA
F:0KE
|
0.006x |
|
ReproCELL Incorporated
F:6RC
|
N/A |
|
Bhiraj Office Leasehold Real Estate Investment Trust
BK:BOFFICE
|
0.023x |
|
Sappe Public Company Limited
BK:SAPPE
|
0.070x |
|
Carlo Gavazzi Holding AG
SW:GAV
|
0.010x |
|
Walchandnagar Industries Limited
NSE:WALCHANNAG
|
0.035x |
|
Compagnie d'Entreprises CFE S.A.
LSE:0O2T
|
-0.007x |
Annual Cash Flow Conversion Efficiency for Alterity Therapeutics Ltd (2002–2025)
The table below shows the annual cash flow conversion efficiency of Alterity Therapeutics Ltd from 2002 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $42.40 Million | $-11.45 Million | -0.270x | +70.44% |
| 2024-06-30 | $13.80 Million | $-12.61 Million | -0.914x | -4.02% |
| 2023-06-30 | $22.81 Million | $-20.04 Million | -0.878x | -152.49% |
| 2022-06-30 | $35.47 Million | $-12.34 Million | -0.348x | +38.84% |
| 2021-06-30 | $30.47 Million | $-17.33 Million | -0.569x | +36.39% |
| 2020-06-30 | $10.55 Million | $-9.43 Million | -0.894x | -6.07% |
| 2019-06-30 | $16.55 Million | $-13.95 Million | -0.843x | -117.06% |
| 2018-06-30 | $16.08 Million | $-6.25 Million | -0.388x | -56.86% |
| 2017-06-30 | $23.69 Million | $-5.87 Million | -0.248x | -4.68% |
| 2016-06-30 | $31.37 Million | $-7.42 Million | -0.237x | +14.91% |
| 2015-06-30 | $39.11 Million | $-10.87 Million | -0.278x | +24.04% |
| 2014-06-30 | $37.69 Million | $-13.79 Million | -0.366x | +35.69% |
| 2013-06-30 | $13.97 Million | $-7.95 Million | -0.569x | +53.26% |
| 2012-06-30 | $5.62 Million | $-6.85 Million | -1.217x | -85.11% |
| 2011-06-30 | $6.93 Million | $-4.56 Million | -0.658x | +26.97% |
| 2010-06-30 | $5.23 Million | $-4.71 Million | -0.900x | +51.72% |
| 2009-06-30 | $3.75 Million | $-6.99 Million | -1.865x | -95.95% |
| 2008-06-30 | $9.89 Million | $-9.41 Million | -0.952x | +41.93% |
| 2007-06-30 | $5.61 Million | $-9.20 Million | -1.639x | -22.82% |
| 2006-06-30 | $8.73 Million | $-11.66 Million | -1.335x | -129.03% |
| 2005-06-30 | $19.51 Million | $-11.37 Million | -0.583x | -321.78% |
| 2004-06-30 | $38.47 Million | $-5.31 Million | -0.138x | +39.11% |
| 2003-06-30 | $15.78 Million | $-3.58 Million | -0.227x | -0.44% |
| 2002-06-30 | $16.68 Million | $-3.77 Million | -0.226x | -- |